** Jefferies revises down health imaging firm Pro Medicus' PME.AX near-term growth forecasts, considering the stepped minimum nature of the Trinity contract
** Brokerage trims firm's cardiology contribution estimates, leading to implied market share increase to 14% in FY26, down 15% from previous estimates
** Despite these adjustments, brokerage maintains its A$250 price target and 'Hold' rating
** Stock down 9% YTD
(Reporting by Kumar Tanishk in Bengaluru)
((Tanishk.Kumar@thomsonreuters.com; X: @thatstanishk;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.